Millions of Medicare beneficiaries who rely on some of the most expensive prescription drugs in the United States will pay sharply less starting January 1, 2027. The Centers for Medicare and Medicaid Services (CMS) reached agreement on negotiated prices for all 15 drugs selected in the second cycle of the Medicare Drug Price Negotiation Program, with reductions ranging from 38% to 85% off current costs. The list includes Ozempic, Wegovy, and Rybelsus, three drugs made by Novo Nordisk that treat diabetes and obesity and have become among the highest-grossing medications in the country.
Why the 2027 negotiated prices change the math for Part D plans
The second-cycle deals cover treatments for cancer, diabetes, and other chronic conditions, and they take effect at the start of 2027. CMS has already published drug-by-drug explanation documents describing the clinical and economic evidence it weighed when setting each maximum fair price. Those explanations give Part D plan sponsors their first detailed look at how the agency valued each medication, information that will shape formulary decisions for the 2027 plan year and beyond.
For plans, the core financial question is how quickly to realign formularies around the new price benchmarks. When a negotiated drug drops by as much as 85%, sponsors face strong incentives to steer enrollees toward it and away from higher-cost alternatives. That can happen through preferred tiers, lower copays, and prior authorization requirements that make non-negotiated competitors harder to access. If this pattern takes hold across major Part D offerings, CMS plan data releases over the next two years should show measurable shifts in formulary exclusions and step-therapy rules for competing products.
This dynamic could narrow treatment choices even as it lowers costs, especially in crowded therapeutic classes like diabetes and cardiovascular disease. Beneficiaries who are stable on a non-negotiated drug may find that staying on it requires higher out-of-pocket spending or additional paperwork. At the same time, lower negotiated prices could reduce premiums and overall program spending, a trade-off that regulators and advocacy groups will be watching closely as 2027 approaches.
CMS evidence trail and Novo Nordisk’s role in the Ozempic deal
Novo Nordisk confirmed its participation in the second negotiation cycle for Ozempic, Rybelsus, and Wegovy, according to a CMS announcement on savings for seniors. The company’s involvement is significant because those three drugs alone account for a large share of Medicare Part D spending on diabetes and weight-management therapies. By agreeing to negotiate rather than face the steep excise tax penalty for refusal, Novo Nordisk accepted price cuts that will ripple through its U.S. revenue projections and potentially its broader pricing strategies.
CMS built its case for each price using a structured review process. The agency’s MFP Explanations section hosts individual documents for every drug, detailing the clinical evidence, therapeutic alternatives, utilization patterns, and manufacturer-specific data the agency considered before setting an initial offer and a final number. Manufacturers could submit counteroffers and additional evidence, but CMS retained authority to determine the maximum fair price within the statutory framework.
The program is also expanding in scope. In a separate release outlining third-cycle drug selections, CMS confirmed that the 2028 negotiation round will include the first Part B drugs. That shift will extend negotiated pricing beyond pharmacy-dispensed medications into physician-administered treatments, such as many infused cancer therapies and biologics given in outpatient settings. For providers and beneficiaries, that could eventually alter buy-and-bill economics and coinsurance obligations in traditional Medicare.
Gaps in the evidence and what to watch before 2027
Several important questions remain unanswered as the 2027 start date approaches. First, it is not yet clear how aggressively Part D plans will move to redesign formularies around the negotiated drugs. Some sponsors may wait to see how competitors respond before making sweeping changes, while others could move quickly to capture savings and market the lower costs to enrollees during open enrollment.
Second, the real-world impact on patient access is still uncertain. CMS has emphasized that negotiated prices are intended to improve affordability, not restrict choice, but the statute does not directly regulate how plans structure utilization management. Advocates will be monitoring whether lower prices translate into fewer denials and smoother access, or whether tighter controls on non-negotiated drugs offset those gains for certain patients.
Third, the long-term effects on drug development and launch strategies are only beginning to emerge. Manufacturers may adjust list prices, introductory discounts, or the timing of Medicare coverage decisions in response to the negotiation timeline. For high-cost specialty drugs nearing eligibility for future negotiation cycles, companies could weigh the likelihood of eventual price cuts against expected sales in the commercial market.
In the near term, beneficiaries and clinicians will need clear communication from plans about how coverage is changing. The 2026 and 2027 plan documents, formulary search tools, and annual notices of change will be the first place most people encounter the practical consequences of the new negotiated prices. Consumer counselors and state health insurance assistance programs will play an important role in helping older adults compare options and understand whether switching drugs-or switching plans-makes sense.
What is certain is that the second negotiation cycle marks a turning point. With double-digit price reductions locked in for some of the most widely used and heavily advertised drugs in the country, Medicare is testing how far it can go in reshaping the prescription drug market while maintaining access. The answers will come not just from federal rulemaking, but from the choices Part D sponsors, manufacturers, providers, and patients make between now and 2027.
